Valuation: Cybin Inc.

Market Cap 1.03B 743M 642M 603M 549M 71.07B 1.05B 7.07B 2.76B 35.59B 2.79B 2.73B 118B P/E 2027 *
-4.53x
P/E 2028 * -5.65x
Enterprise Value 598M 431M 372M 350M 318M 41.2B 608M 4.1B 1.6B 20.63B 1.62B 1.58B 68.55B EV / Sales 2027 *
-
EV / Sales 2028 * 41.1x
Free-Float
-
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Cybin Inc.

1 day+4.72%
1 week+3.27%
Current month+53.32%
1 month+79.49%
3 months+136.96%
6 months+96.88%
Current year+46.58%
1 week 9.84
Extreme 9.835
12.02
1 month 6.77
Extreme 6.7655
12.02
Current year 3.76
Extreme 3.76
12.02
1 year 3.76
Extreme 3.76
12.02
3 years 3.76
Extreme 3.76
28.04
5 years 3.76
Extreme 3.76
109.44
10 years 3.76
Extreme 3.76
128.44
Manager TitleAgeSince
Chief Executive Officer 51 2025-09-01
Chief Operating Officer 37 2016-10-12
Chief Executive Officer 53 2026-08-02
Director TitleAgeSince
Chairman 51 2020-11-04
Director/Board Member 37 2016-10-12
Director/Board Member 65 2020-11-04
Date Insider Type Main position Quantity % Market Cap.
8/3/26 Other

Chief Executive Officer

0 0%
8/3/26 Other

Chief Executive Officer

0 0%
7/13/26 Buy

Chief Financial Officer

-70,550 0.1410%
Change 5-day change 1-year change 3-year change Capi.($)
+4.72%+3.27%+67.22%-7.20% 710M
-1.90%+2.85%+61.37%+102.88% 71.56B
-3.21%-4.32%+31.19%+59.75% 54.43B
-2.05%-5.61%-3.14%+454.89% 27.59B
-1.27%-1.57%+46.46%+6.09% 23.91B
+1.05%-0.62%-17.40%-13.36% 23.14B
+0.10%+1.40%+38.98%-20.04% 18.65B
+3.81%+20.97%+263.48%+552.47% 18.64B
-0.95%-3.52%+20.04%+613.01% 16.01B
+1.24%-5.23%+33.19%+138.21% 12.54B
Average +0.15%+2.07%+54.14%+188.67% 26.72B
Weighted average by Cap. -1.11%+0.49%+49.16%+166.43%

Financials

2027 *2028 *
Net sales - 11.2M 8.07M 6.97M 6.55M 5.96M 772M 11.39M 76.77M 30.02M 387M 30.31M 29.65M 1.28B
Net income -248M -179M -154M -145M -132M -17.09B -252M -1.7B -665M -8.56B -671M -657M -28.45B -255M -184M -159M -149M -136M -17.57B -259M -1.75B -683M -8.8B -690M -675M -29.23B
Net Debt -433M -312M -270M -254M -231M -29.87B -441M -2.97B -1.16B -14.96B -1.17B -1.15B -49.71B -571M -412M -355M -334M -304M -39.35B -580M -3.91B -1.53B -19.7B -1.54B -1.51B -65.48B
Logo Cybin Inc.
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Employees
100
Date Price Change Volume
26-08-14 US$11.99 +4.72% 1,511,443
26-08-13 US$11.45 -0.35% 1,940,081
26-08-12 US$11.49 +13.88% 3,237,440
26-08-11 US$10.09 +0.80% 988,041
26-08-10 US$10.01 -13.78% 3,129,023
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
16.64CAD
Average target price
49.33CAD
Spread / Average Target
+196.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HELP Stock